Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Michael R. Mancuso, … , Dana D. Hu-Lowe, Donald M. McDonald
Michael R. Mancuso, … , Dana D. Hu-Lowe, Donald M. McDonald
Published October 2, 2006
Citation Information: J Clin Invest. 2006;116(10):2610-2621. https://doi.org/10.1172/JCI24612.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 7

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

  • Text
  • PDF
Abstract

Inhibitors of VEGF signaling can block angiogenesis and reduce tumor vascularity, but little is known about the reversibility of these changes after treatment ends. In the present study, regrowth of blood vessels in spontaneous RIP-Tag2 tumors and implanted Lewis lung carcinomas in mice was assessed after inhibition of VEGF receptor signaling by AG-013736 or AG-028262 for 7 days. Both agents caused loss of 50%–60% of tumor vasculature. Empty sleeves of basement membrane were left behind. Pericytes also survived but had less α–SMA immunoreactivity. One day after drug withdrawal, endothelial sprouts grew into empty sleeves of basement membrane. Vessel patency and connection to the bloodstream followed close behind. By 7 days, tumors were fully revascularized, and the pericyte phenotype returned to baseline. Importantly, the regrown vasculature regressed as much during a second treatment as it did in the first. Inhibition of MMPs or targeting of type IV collagen cryptic sites by antibody HUIV26 did not eliminate the sleeves or slow revascularization. These results suggest that empty sleeves of basement membrane and accompanying pericytes provide a scaffold for rapid revascularization of tumors after removal of anti-VEGF therapy and highlight their importance as potential targets in cancer therapy.

Authors

Michael R. Mancuso, Rachel Davis, Scott M. Norberg, Shaun O’Brien, Barbara Sennino, Tsutomu Nakahara, Virginia J. Yao, Tetsuichiro Inai, Peter Brooks, Bruce Freimark, David R. Shalinsky, Dana D. Hu-Lowe, Donald M. McDonald

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Total
Citations: 5 16 13 13 22 17 14 13 18 20 28 19 22 31 29 36 21 12 12 1 362
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (363)

Title and authors Publication Year
Predicting Outcomes in Esophageal Squamous Cell Carcinoma Using scRNA‐Seq and Bulk RNA‐Seq: A Model Development and Validation Study
Zhang J, Song S, Li Y, Gong A
Cancer Medicine 2025
Pericytes in hematogenous metastasis: mechanistic insights and therapeutic approaches.
Xu S, Zhang H, Tian Y
Cellular oncology (Dordrecht, Netherlands) 2025
Angiogenesis, signaling pathways, and animal models.
Jensen L, Guo Z, Sun X, Jing X, Yang Y, Cao Y
Chinese medical journal 2025
Hemorrhagic and ischemic risks of anti-VEGF therapies in glioblastoma.
Beylerli O, Gareev I, Kaprin A, Ahmad A, Chekhonin V, Yang S, Yang G
Cancer gene therapy 2025
Myeloid ACAT1/SOAT1: a novel regulator of dyslipidemia and retinal neovascularization
Zaidi SA, Caldwell RB, Rojas MA
npj Metabolic Health and Disease 2025
RAB4A-directed endosome traffic controls autoimmunity during lupus pathogenesis via MTOR activation and proinflammatory mitochondrial metabolism
Nick Huang, Thomas Winans, Brandon Wyman, Zachary Oaks, Tamas Faludi, Gourav Choudhary, Miguel Beckford, Manuel Duarte, Joshua Lewis, Daniel Krakko, Akshay Patel, Laurence Morel, Mark Haas, Frank Middleton, Katalin Banki, Andras Perl
Nature Communications 2024
Endothelial TDP-43 controls sprouting angiogenesis and vascular barrier integrity, and its deletion triggers neuroinflammation
Víctor Arribas, Yara Onetti, Marina Ramiro-Pareta, Pilar Villacampa, Heike Beck, Mariona Alberola, Anna Esteve-Codina, Markus Sperandio, Ofelia M. Martínez-Estrada, Bettina Schmid, Eloi Montanez
JCI Insight 2024
Pattern recognition of microcirculation with super-resolution ultrasound imaging provides markers for early tumor response to anti-angiogenic therapy
Yin J, Dong F, An J, Guo T, Cheng H, Zhang J, Zhang J
Theranostics 2024
Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design
Sener U, Islam M, Webb M, Kizilbash SH
2024
Experimental and theoretical model of microvascular network remodeling and blood flow redistribution following minimally invasive microvessel laser ablation.
Gruionu G, Baish J, McMahon S, Blauvelt D, Gruionu LG, Lenco MO, Vakoc BJ, Padera TP, Munn LL
Scientific Reports 2024
A vascularized breast cancer spheroid platform for the ranked evaluation of tumor microenvironment-targeted drugs by light sheet fluorescence microscopy
Ascheid D, Baumann M, Pinnecker J, Friedrich M, Szi-Marton D, Medved C, Bundalo M, Ortmann V, Öztürk A, Nandigama R, Hemmen K, Ergün S, Zernecke A, Hirth M, Heinze KG, Henke E
Nature Communications 2024
Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options.
Nunes M, Bartosch C, Abreu MH, Richardson A, Almeida R, Ricardo S
Cells 2024
A Phase IIa Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium
Whitcup SM, Sall KN, Hovanesian JA, Goldberg DF, Lee OL, Yang R, Ni J
2024
Monitoring imatinib decreasing pericyte coverage and HIF-1α level in a colorectal cancer model by an ultrahigh-field multiparametric MRI approach.
Hu X, Ye K, Bo S, Xiao Z, Ma M, Pan J, Zhong X, Zhang D, Mo X, Yu X, Chen M, Luo L, Shi C
Journal of Translational Medicine 2024
The role of extracellular matrix in angiogenesis: Beyond adhesion and structure.
Libby JR, Royce H, Walker SR, Li L
2024
Laminin Beta 2 Is Localized at the Sites of Blood-Brain Barrier and Its Disruption Is Associated With Increased Vascular Permeability, Histochemical, and Transcriptomic Study.
Bannykh KS, Fuentes-Fayos AC, Linesch PW, Breunig JJ, Bannykh SI
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2024
Intraperitoneal Chemotherapy without Bevacizumab versus Intravenous Chemotherapy with Bevacizumab as the Frontline Adjuvant Therapy in Advanced Ovarian Cancer
Ting WH, Chen HH, Wei MC, Sun HD, Hsiao SM
Cancers 2024
Milestones in tumor vascularization and its therapeutic targeting.
De Palma M, Hanahan D
Nature cancer 2024
Efficacy and safety of anti-angiogenic drugs combined with chemotherapy in the treatment of platinum-sensitive/resistant ovarian cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
He H, Zhou F
Frontiers in Pharmacology 2024
Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer
Lin QX, Song WW, Xie WX, Deng YT, Gong YN, Liu YR, Tian Y, Zhao WY, Tian L, Gu DN
Neoplasia (New York, N.Y.) 2024
Research progress on platelets in glioma
Zuo M, Li T, Wang Z, Xiang Y, Chen S, Liu Y
Chinese Medical Journal 2024
Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
Jeon H, Byun J, Kang H, Kim K, Lee E, Kim JH, Hong CK, Song SW, Kim YH, Chong S, Kim JH, Nam SJ, Park JE, Lee S
Journal of Translational Medicine 2023
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Lang M, Longerich T, Anamaterou C
Thyroid Research 2023
Persistence of vascular empty sleeves in choroidal neovascularization after VEGF therapy in both animal models and humans.
Wada I, Nakao S, Fukuda Y, Shiose S, Takeda A, Kannan R, Sonoda KH
2023
Targeting angiogenesis in oncology, ophthalmology and beyond.
Cao Y, Langer R, Ferrara N
Nature reviews. Drug discovery 2023
Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule.
Grimaudo MS, Laffi A, Gennaro N, Fazio R, D'Orazio F, Samà L, Siracusano LV, Sicoli F, Renne SL, Santoro A, Bertuzzi AF
Frontiers in Oncology 2023
Tumour associated endothelial cells: origin, characteristics and role in metastasis and anti-angiogenic resistance
Yao X, Zeng Y
Frontiers in physiology 2023
Update on immune‐based therapy strategies targeting cancer stem cells
Izadpanah A, Mohammadkhani N, Masoudnia M, Ghasemzad M, Saeedian A, Mehdizadeh H, Poorebrahim M, Ebrahimi M
Cancer Medicine 2023
Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients
Webb MJ, Neth BJ, Webb LM, Van Gompel JJ, Link MJ, Neff BA, Carlson ML, Driscoll CL, Dornhoffer J, Ruff MW, Anderson KA, Kizilbash SH, Campian JL, Uhm JH, Lane JI, Benson JC, Blezek DJ, Mehta PM, Bathla G, Sener UT
2023
Dose-specific intratumoral GM-CSF modulates breast tumor oxygenation and anti-tumor immunity
Mihalik NE, Steinberger KJ, Stevens AM, Bobko AA, Hoblitzell EH, Tseytlin O, Akhter H, Dziadowicz SA, Wang L, O\u2019Connell RC, Monaghan KL, Hu G, Mo X, Khramtsov VV, Tseytlin M, Driesschaert B, Wan EC, Eubank TD
Journal of immunology (Baltimore, Md. : 1950) 2023
Vascular co-option in resistance to anti-angiogenic therapy
Ribatti D, Annese T, Tamma R
Frontiers in Oncology 2023
Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy-A Translational Model.
Swamy K
Human vaccines 2023
MTOR-DEPENDENT LOSS OF PON1 SECRETION AND ANTIPHOSPHOLIPID AUTOANTIBODY PRODUCTION UNDERLIE AUTOIMMUNITY-MEDIATED CIRRHOSIS IN TRANSALDOLASE DEFICIENCY
Winans T, Oaks Z, Choudhary G, Patel A, Huang N, Faludi T, Krakko D, Nolan J, Lewis J, Sarah B, Lai Z, Landas S, Middleton F, Asara J, Chung S, Wyman B, Azadi P, Banki K, Perl A
Journal of Autoimmunity 2023
Extracellular Matrix Regulation of Vascular Morphogenesis, Maturation, and Stabilization
Davis GE, Kemp SS
Cold Spring Harbor Perspectives in Medicine 2023
Challenges and Opportunities Associated With Platelets in Pancreatic Cancer
Z Chen, X Wei, S Dong, F Han, R He, W Zhou
Frontiers in Oncology 2022
SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors.
Wang X, Chen Z, Xu J, Tang S, An N, Jiang L, Zhang Y, Zhang S, Zhang Q, Shen Y, Chen S, Lan X, Wang T, Zhai L, Cao S, Guo S, Liu Y, Bi A, Chen Y, Gai X, Duan Y, Zheng Y, Fu Y, Li Y, Yuan L, Tong L, Mo K, Wang M, Lin SH, Tan M, Luo C, Chen Y, Liu J, Zhang Q, Li L, Huang M
Cell Research 2022
Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy
Schiffmann LM, Bruns CJ, Schmidt T
Frontiers in Oncology 2022
mRNA-miRNA bipartite networks reconstruction in different tissues of bladder cancer based on gene co-expression network analysis.
Abedi Z, MotieGhader H, Hosseini SS, Sheikh Beig Goharrizi MA, Masoudi-Nejad A
Scientific Reports 2022
Apoptosis induction in human lung and colon cancer cells via impeding VEGF signaling pathways.
Farzaneh Behelgardi M, Gholami Shahvir Z, Asghari SM
Molecular Biology Reports 2022
Mechanisms of chemotherapy resistance in ovarian cancer
Ortiz M, Wabel E, Mitchell K, Horibata S
2022
A rare case of metastatic atypical meningioma that highlights the shortcomings of treatment options at present
Wrange EK, Harders SM
Acta Radiologica Open 2022
Necrotizing Fasciitis In A Patient with Metastatic Clear Cell Ovarian Carcinoma Treated with Bevacizumab.
Haider A, Gurjar H, Ghazanfar H, Chilimuri S
2022
A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.
Ju WT, Xia RH, Zhu DW, Dou SJ, Zhu GP, Dong MJ, Wang LZ, Sun Q, Zhao TC, Zhou ZH, Liang SY, Huang YY, Tang Y, Wu SC, Xia J, Chen SQ, Bai YZ, Li J, Zhu Q, Zhong LP
Nature Communications 2022
Neuropilin-1 modulates the 3D invasive properties of glioblastoma stem-like cells
Kerhervé M, Rosińska S, Trillet K, Zeinaty A, Feyeux M, Nedellec S, Gavard J
Frontiers in Cell and Developmental Biology 2022
Vascular normalization and immunotherapy: Spawning a virtuous cycle
Swamy K
Frontiers in Oncology 2022
Assessment of mouse VEGF neutralization by ranibizumab and aflibercept
Ichiyama Y, Matsumoto R, Obata S, Sawada O, Saishin Y, Kakinoki M, Sawada T, Ohji M
PloS one 2022
Dynamic Contrast-Enhanced Ultrasound Modeling of an Analog to Pseudo-Diffusivity in Intravoxel Incoherent Motion Magnetic Resonance Imaging
Hristov D, Mustonen L, von Eyben R, Götschel S, Minion M, El Kaffas A
IEEE Transactions on Medical Imaging 2022
Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages
M Reis-Sobreiro, AT da Mota, C Jardim, K Serre
Cells 2021
Anti-VEGF agents: As appealing targets in the setting of COVID-19 treatment in critically ill patients
A Sahebnasagh, SM Nabavi, HR Kashani, S Abdollahian, S Habtemariam, A Rezabakhsh
International Immunopharmacology 2021
Relapse of pathological angiogenesis: functional role of the basement membrane and potential treatment strategies
A Mukwaya, L Jensen, N Lagali
Experimental & molecular medicine 2021
Perivascular cell‐derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs
M Huang, M Chen, M Qi, G Ye, J Pan, C Shi, Y Yang, L Zhao, X Mo, Y Zhang, Y Li, J Zhong, W Lu, X Li, J Zhang, J Lin, L Luo, T Liu, PM Tang, A Hong, Y Cao, W Ye, D Zhang
Journal of Extracellular Vesicles 2021
Therapeutic targeting of the hypoxic tumour microenvironment
DC Singleton, A Macann, WR Wilson
Nature Reviews Clinical Oncology 2021
Blood Vessels and Peripheral Nerves as Key Players in Cancer Progression and Therapy Resistance
N Roda, G Blandano, PG Pelicci
Cancers 2021
Effect of Peptide Receptor Radionuclide Therapy in Combination with Temozolomide against Tumor Angiogenesis in a Glioblastoma Model
SH Lee, JY Choi, JH Jung, IH Song, HS Park, N Denora, F Leonetti, SE Kim, BC Lee
Cancers 2021
Effect of Synchronous Versus Sequential Regimens on the Pharmacokinetics and Biodistribution of Regorafenib with Irradiation
TH Tsai, YJ Chen, LY Wang, CH Hsieh
Pharmaceutics 2021
Mathematical simulation of tumour angiogenesis: angiopoietin balance is a key factor in vessel growth and regression
H Yanagisawa, M Sugimoto, T Miyashita
Scientific Reports 2021
Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing
T Inoue, T Byrne, M Inoue, ME Tait, P Wall, A Wang, MR Dermyer, H Laklai, JJ Binder, C Lees, R Hollingsworth, L Maruri-Avidal, DH Kirn, DM McDonald
Molecular cancer therapeutics 2021
The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer
D Ribatti, AG Solimando, F Pezzella
Cancers 2021
Molecular Docking and Dynamics Simulation Revealed Ivermectin as Potential Drug against Schistosoma-Associated Bladder Cancer Targeting Protein Signaling: Computational Drug Repositioning Approach
AJ Siddiqui, MF Khan, WS Hamadou, M Goyal, S Jahan, A Jamal, SA Ashraf, P Sharma, M Sachidanandan, R Badraoui, KK Chaubey, M Snoussi, M Adnan
Medicina 2021
Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
TF Hansen, C Qvortrup, P Pfeiffer
Cancers 2021
Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature
A Hooglugt, MM van der Stoel, RA Boon, S Huveneers
Frontiers in Oncology 2021
Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience
HJ Jiang, YH Chang, YH Chen, CW Wu, PW Wang, PJ Hsiao
Cancer management and research 2021
The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer
AD Murphy, RD Morgan, AR Clamp, GC Jayson
British Journal of Cancer 2021
Management of VEGFR-Targeted TKI for Thyroid Cancer
T Enokida, M Tahara
Cancers 2021
Invasive procedures in patients undergoing treatment with lenvatinib for thyroid cancer
S Toda, H Iwasaki, D Murayama, H Nakayama, N Suganuma, K Masudo
Molecular and Clinical Oncology 2021
Pneumatosis intestinalis associated with lenvatinib during thyroid cancer treatment: a case report
S Toda, H Iwasaki, D Murayama, M Isoda, H Nakayama, N Suganuma, K Masudo
Journal of medical case reports 2021
Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs.
Jiang P, Zhang Y, Cui J, Wang X, Li Y
Thoracic Cancer 2021
Myofibre injury induces capillary disruption and regeneration of disorganized microvascular networks
Jacobsen NL, Norton CE, Shaw RL, Cornelison DD, Segal SS
The Journal of Physiology 2021
Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study
Gonzalez VH, Berger B, Goldberg R, Gordon CM, Khurana RN, Angeles R, Shams N
Translational Vision Science & Technology 2021
Blocking endothelial apoptosis revascularises the retina in a model of ischemic retinopathy
Zoe L. Grant, Lachlan Whitehead, Vickie H. Y. Wong, Zheng He, Richard Y. Yan, Abigail R. Miles, Andrew V. Benest, David O. Bates, Claudia Prahst, Katie Bentley, Bang V. Bui, Robert C.A. Symons, Leigh Coultas
Journal of Clinical Investigation 2020
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
XD Liu, W Kong, CB Peterson, DJ McGrail, A Hoang, X Zhang, T Lam, PG Pilie, H Zhu, KE Beckermann, SM Haake, S Isgandrova, M Martinez-Moczygemba, N Sahni, NM Tannir, SY Lin, WK Rathmell, E Jonasch
Nature Communications 2020
MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis
SK Das, S Maji, SL Wechman, P Bhoopathi, AK Pradhan, S Talukdar, D Sarkar, J Landry, C Guo, XY Wang, WK Cavenee, L Emdad, PB Fisher
Pharmacological research : the official journal of the Italian Pharmacological Society 2020
Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth
AK Azad, P Zhabyeyev, B Vanhaesebroeck, G Eitzen, GY Oudit, RB Moore, AG Murray
Oncogene 2020
Functional Interplay Between Collagen Network and Cell Behavior Within Tumor Microenvironment in Colorectal Cancer
CC Le, A Bennasroune, B Langlois, S Salesse, C Boulagnon-Rombi, H Morjani, S Dedieu, A Appert-Collin
Frontiers in Oncology 2020
Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer‐bearing mice and patients
M Liu, H Li, X Wang, L Jing, P Jiang, Y Li
Cancer Medicine 2020
Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer
A Sasaki, K Harano, T Kogawa, N Matsubara, Y Naito, A Hosono, H Mukai, T Yoshino, T Mukohara
Case Reports in Oncological Medicine 2020
Pericyte Bridges in Homeostasis and Hyperglycemia
BA Corliss, HC Ray, RW Doty, C Mathews, N Sheybani, K Fitzgerald, R Prince, MR Kelly-Goss, WL Murfee, J Chappell, GK Owens, PA Yates, SM Peirce
Diabetes 2020
Pericytes in Vascular Development
LB Payne, M Hoque, C Houk, J Darden, JC Chappell
2020
A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
H Iwasaki, S Toda, H Ito, D Nemoto, D Murayama, Y Okubo, H Hayashi, T Yokose
Case Reports in Endocrinology 2020
Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension
MP Winter, S Sharma, J Altmann, V Seidl, A Panzenböck, A Alimohammadi, T Zelniker, B Redwan, F Nagel, D Santer, A Stieglbauer, B Podesser, M Sibilia, T Helbich, G Prager, A Ilhan-Mutlu, M Preusser, IM Lang
Basic Research in Cardiology 2020
Modulation of vascular response after injury in the rat Achilles tendon alters healing capacity
CN Riggin, AB Rodriguez, SN Weiss, HA Raja, M Chen, SM Schultz, CM Sehgal, LJ Soslowsky
Journal of orthopaedic research : official publication of the Orthopaedic Research Society 2020
‘There and Back Again’—Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension
EM Swietlik, M Prapa, JM Martin, D Pandya, K Auckland, NW Morrell, S Gräf
Genes & development 2020
ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
DH Yeom, YS Lee, I Ryu, S Lee, B Sung, HB Lee, D Kim, JH Ahn, E Ha, YS Choi, SH Lee, WK You
International journal of molecular sciences 2020
Balanced Wnt/Dickkopf1 signaling by mesenchymal vascular progenitor cells in the microvascular niche maintains distal lung structure and function
ME Summers, BW Richmond, JA Kropski, SA Majka, JA Bastarache, AK Hatzopoulos, J Bylund, M Ghosh, I Petrache, RF Foronjy, P Geraghty, SM Majka
American journal of physiology. Cell physiology 2020
Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment
CO Madu, S Wang, CO Madu, Y Lu
Journal of Cancer 2020
Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis
H Iwasaki, S Toda, D Murayama, S Kato, A Matsui
Molecular and Clinical Oncology 2020
Synergy Between Low Dose Metronomic Chemotherapy and the pH-centered Approach Against Cancer
Koltai, Cardone, Reshkin
International journal of molecular sciences 2019
Pericyte Biology in Disease
A Birbrair
2019
Stem cell exosomes inhibit angiogenesis and tumor growth of oral squamous cell carcinoma
L Rosenberger, M Ezquer, F Lillo-Vera, PL Pedraza, MI Ortúzar, PL González, AI Figueroa-Valdés, J Cuenca, F Ezquer, M Khoury, F Alcayaga-Miranda
Scientific Reports 2019
KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib
G Wang, Y Huang, Z Wu, C Zhao, H Cong, S Ju, X Wang
Bioscience Reports 2019
Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2‑negative breast cancer: A meta‑analysis of randomized controlled trials
Z Nahleh, G Botrus, A Dwivedi, M Jennings, S Nagy, A Tfayli
Molecular and Clinical Oncology 2019
Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept
E Ciruelos, JM Pérez-García, J Gavilá, A Rodríguez, J de la Haba-Rodriguez
Clinical Drug Investigation 2019
Ultrasound Evaluation of Anti-Vascular Endothelial Growth Factor–Induced Changes in Vascular Response Following Tendon Injury
CN Riggin, SM Schultz, CM Sehgal, LJ Soslowsky
Ultrasound in Medicine & Biology 2019
Intussusceptive Vascular Remodeling Precedes Pathological Neovascularization
Z Ali, A Mukwaya, A Biesemeier, M Ntzouni, D Ramsköld, S Giatrellis, P Mammadzada, R Cao, A Lennikov, M Marass, C Gerri, C Hildesjö, M Taylor, Q Deng, B Peebo, L del Peso, A Kvanta, R Sandberg, U Schraermeyer, H Andre, JF Steffensen, N Lagali, Y Cao, J Kele, LD Jensen
Arteriosclerosis, thrombosis, and vascular biology 2019
Pazopanib in advanced soft tissue sarcomas
AT Lee, RL Jones, PH Huang
Signal Transduction and Targeted Therapy 2019

Epigallocatechin-3-gallate-induced vascular normalization in A549-cell xenograft-bearing nude mice: therapeutic efficacy in combination with chemotherapy


P Deng, CP Hu, Z Xiong, Y Li, J Jiang, H Yang, Y Tang, L Cao, R Lu
Cancer management and research 2019
Editorial on “The AvaALL Randomized Clinical Trial”
L Bonanno, A Pavan, G Pasello, S Indraccolo
Journal of Thoracic Disease 2019
Alternative Strategies to Inhibit Tumor Vascularization
A Brossa, L Buono, S Fallo, AF Pla, L Munaron, B Bussolati
International journal of molecular sciences 2019
Revascularization after angiogenesis inhibition favors new sprouting over abandoned vessel reuse
A Mukwaya, P Mirabelli, A Lennikov, M Thangavelu, M Ntzouni, L Jensen, B Peebo, N Lagali
Angiogenesis 2019
The pro-tumorigenic host response to cancer therapies
Y Shaked
Nature Reviews Cancer 2019
LOX-catalyzed collagen stabilization is a proximal cause for intrinsic resistance to chemotherapy
L Rossow, S Veitl, S Vorlová, JK Wax, AE Kuhn, V Maltzahn, B Upcin, F Karl, H Hoffmann, S Gätzner, M Kallius, R Nandigama, D Scheld, S Irmak, S Herterich, A Zernecke, S Ergün, E Henke
Oncogene 2018
Consensus guidelines for the use and interpretation of angiogenesis assays
P Nowak-Sliwinska, K Alitalo, E Allen, A Anisimov, AC Aplin, R Auerbach, HG Augustin, DO Bates, JR van Beijnum, RH Bender, G Bergers, A Bikfalvi, J Bischoff, BC Böck, PC Brooks, F Bussolino, B Cakir, P Carmeliet, D Castranova, AM Cimpean, O Cleaver, G Coukos, GE Davis, MD Palma, A Dimberg, RP Dings, V Djonov, AC Dudley, NP Dufton, SM Fendt, N Ferrara, M Fruttiger, D Fukumura, B Ghesquière, Y Gong, RJ Griffin, AL Harris, CC Hughes, NW Hultgren, ML Iruela-Arispe, M Irving, RK Jain, R Kalluri, J Kalucka, RS Kerbel, J Kitajewski, I Klaassen, HK Kleinmann, P Koolwijk, E Kuczynski, BR Kwak, K Marien, JM Melero-Martin, LL Munn, RF Nicosia, A Noel, J Nurro, AK Olsson, TV Petrova, K Pietras, R Pili, JW Pollard, MJ Post, PH Quax, GA Rabinovich, M Raica, AM Randi, D Ribatti, C Ruegg, RO Schlingemann, S Schulte-Merker, LE Smith, JW Song, SA Stacker, J Stalin, AN Stratman, MV de Velde, VW van Hinsbergh, PB Vermeulen, J Waltenberger, BM Weinstein, H Xin, B Yetkin-Arik, S Yla-Herttuala, MC Yoder, AW Griffioen
Angiogenesis 2018
Biomimetic microfluidic platform for the quantification of transient endothelial monolayer permeability and therapeutic transport under mimicked cancerous conditions
CG Uhl, VR Muzykantov, Y Liu
Biomicrofluidics 2018
Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer
J Pawel, DR Spigel, T Ervin, G Losonczy, F Barlesi, E Juhász, M Anderson, B McCall, E Wakshull, P Hegde, W Ye, D Chen, I Chang, I Rhee, M Reck
The oncologist 2018
Microfluidics in Malignant Glioma Research and Precision Medicine
M Logun, W Zhao, L Mao, L Karumbaiah
Advanced Biosystems 2018
The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib
JM Hudson, C Bailey, M Atri, G Stanisz, L Milot, R Williams, A Kiss, PN Burns, GA Bjarnason
European Radiology 2018
Blockade of TREM-1 prevents vitreoretinal neovascularization in mice with oxygen-induced retinopathy
MA Rojas, ZT Shen, RB Caldwell, AB Sigalov
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018
Discontinuous Schedule of Bevacizumab in Colorectal Cancer Induces Accelerated Tumor Growth and Phenotypic Changes
S Becherirat, F Valamanesh, M Karimi, AM Faussat, JM Launay, C Pimpie, A Therwath, M Pocard
Translational oncology 2018
Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
M Delgado-Ureña, FG Ortega, D de Miguel-Pérez, A Rodriguez-Martínez, JL García-Puche, H Ilyine, JA Lorente, J Exposito-Hernandez, MC Garrido-Navas, M Delgado-Ramirez, MJ Serrano
Journal of Translational Medicine 2018
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
A Maráz, A Cserháti, G Uhercsák, É Szilágyi, Z Varga, J Révész, R Kószó, L Varga, Z Kahán
BMC Cancer 2018
Customizable biomaterials as tools for advanced anti-angiogenic drug discovery
EH Nguyen, WL Murphy
Biomaterials 2018
Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells
A Brossa, L Buono, B Bussolati
Oncotarget 2018
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study
A Bamias, V Karavasilis, N Gavalas, K Tzannis, E Samantas, G Aravantinos, A Koutras, I Gkerzelis, E Kostouros, K Koutsoukos, F Zagouri, G Fountzilas, MA Dimopoulos
International Journal of Clinical Oncology 2018
Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression
HJ Dalton, S Pradeep, M McGuire, Y Hailemichael, S MA, Y Lyons, GN Armaiz-Pena, RA Previs, JM Hansen, R Rupaimoole, V Gonzalez-Villasana, MS Cho, SY Wu, LS Mangala, NB Jennings, W Hu, R Langley, H Mu, M Andreeff, M Bar-Eli, W Overwijk, P Ram, G Lopez-Berestein, RL Coleman, AK Sood
Clinical cancer research 2017
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
M Pinter, RK Jain
Science Translational Medicine 2017
A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
LM Schiffmann, M Brunold, M Liwschitz, V Goede, S Loges, M Wroblewski, A Quaas, H Alakus, D Stippel, CJ Bruns, M Hallek, H Kashkar, UT Hacker, O Coutelle
British Journal of Cancer 2017
Microenvironmental regulation of tumour angiogenesis
MD Palma, D Biziato, TV Petrova
Nature Reviews Cancer 2017
A mathematical model of tumour angiogenesis: growth, regression and regrowth
G Vilanova, I Colominas, H Gomez
Journal of The Royal Society Interface 2017
Incorporating VEGF-targeted therapy in advanced urothelial cancer
S Narayanan, S Srinivas
Therapeutic advances in medical oncology 2017
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents
RK Pavana, S Choudhary, A Bastian, MA Ihnat, R Bai, E Hamel, A Gangjee
Bioorganic & Medicinal Chemistry 2017
Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study
N Snoeren, R Hillegersberg, SB Schouten, AM Bergman, E Werkhoven, O Dalesio, RA Tollenaar, HM Verheul, J der Sijp, IH Rinkes, EE Voest
Neoplasia (New York, N.Y.) 2017
Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial
EJ Hovey, KM Field, MA Rosenthal, EH Barnes, L Cher, AK Nowak, H Wheeler, K Sawkins, A Livingstone, P Phal, C Goh, J Simes
Neuro-Oncology Practice 2017
Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy
Y Zhang, M Sun, G Huang, L Yin, Q Lai, Y Yang, X Xing, G Yu, Y Sun, X Wang, G Nie, Y Liu, Y Cao
Proceedings of the National Academy of Sciences 2017
Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression
M Kondo, K Numata, K Hara, A Nozaki, H Fukuda, M Chuma, S Maeda, K Tanaka
Gastroenterology Research and Practice 2017
Anti- angiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies – A review
AM Al-Abd, AJ Alamoudi, AB Abdel-Naim, TA Neamatallah, OM Ashour
Journal of Advanced Research 2017
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
E Molinaro, C Romei, A Biagini, E Sabini, L Agate, S Mazzeo, G Materazzi, S Sellari-Franceschini, A Ribechini, L Torregrossa, F Basolo, P Vitti, R Elisei
Nature Reviews Endocrinology 2017
Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers
M Bréchon, M Dior, J Dréanic, B Brieau, MA Guillaumot, C Brezault, O Mir, F Goldwasser, R Coriat
Investigational New Drugs 2017
Nanotechnology as a Delivery Tool for Precision Cancer Therapies
B Sharma, RM Crist, PP Adiseshaiah
The AAPS Journal 2017
Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer
R GarcíaCarbonero, E Cutsem, F Rivera, J Jassem, I Gore, N Tebbutt, F Braiteh, G Argiles, ZA Wainberg, R Funke, M Anderson, B McCall, M Stroh, E Wakshull, P Hegde, W Ye, D Chen, I Chang, I Rhee, H Hurwitz
The oncologist 2017
Electroacupuncture improves neurovascular unit reconstruction by promoting collateral circulation and angiogenesis
L Shi, H Cao, Y Li, S Xu, Y Zhang, Y Zhang, Z Jin
NEURAL REGEN RES 2017
Targeting Intramembrane Protein-Protein Interactions: Novel Therapeutic Strategy of Millions Years Old.
Sigalov AB
Advances in protein chemistry and structural biology 2017
FAK regulates platelet-extravasation and tumor growth after anti-angiogenic therapy withdrawal
Monika Haemmerle, Justin Bottsford-Miller, Sunila Pradeep, Morgan L. Taylor, Hyun-Jin Choi, Jean Hansen, Heather J. Dalton, Rebecca L. Stone, Min Soon Cho, Alpa M. Nick, Archana S. Nagaraja, Tony Gutschner, Kshipra M. Gharpure, Lingegowda Mangala, Rajesha Rupaimoole, HEE DONG HAN, Behrouz Zand, Guillermo N. Armaiz-Pena, Sherry Wu, Chad Pecot, Alan R. Burns, Gabriel Lopez-Berestein, Vahid Afshar-Kharghan, Anil Sood
Journal of Clinical Investigation 2016
HIF-2α Expression Regulates Sprout Formation into 3D Fibrin Matrices in Prolonged Hypoxia in Human Microvascular Endothelial Cells
TD Nauta, MC Duyndam, EM Weijers, VM van Hinsbergh, P Koolwijk, M Ushio-Fukai
PloS one 2016
Identification of HIF-2α-regulated genes that play a role in human microvascular endothelial sprouting during prolonged hypoxia in vitro
TD Nauta, M Broek, S Gibbs, TC van der Pouw-Kraan, CB Oudejans, VW van Hinsbergh, P Koolwijk
Angiogenesis 2016
Pericytes, an overlooked player in vascular pathobiology
D Ferland-McCollough, S Slater, J Richard, C Reni, G Mangialardi
Pharmacology & Therapeutics 2016
Flt-1 (VEGFR-1) coordinates discrete stages of blood vessel formation
JC Chappell, JG Cluceru, JE Nesmith, KP Mouillesseaux, VB Bradley, CM Hartland, YL Hashambhoy-Ramsay, J Walpole, SM Peirce, FM Gabhann, VL Bautch
Cardiovascular Research 2016
The biomechanical properties of an epithelial tissue determine the location of its vasculature
M Kragl, R Schubert, H Karsjens, S Otter, B Bartosinska, K Jeruschke, J Weiss, C Chen, D Alsteens, O Kuss, S Speier, D Eberhard, DJ Müller, E Lammert
Nature Communications 2016
Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects
Y Shaked
Nature Reviews Clinical Oncology 2016
The Role of RhoJ in Endothelial Cell Biology and Tumor Pathology
TT Shi, G Li, HT Xiao
BioMed Research International 2016
Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS)
U Ronellenfitsch, A Dimitrakopoulou-Strauss, J Jakob, B Kasper, K Nowak, LR Pilz, U Attenberger, T Gaiser, G Egerer, S Fröhling, HG Derigs, M Schwarzbach, P Hohenberger
BMJ Open 2016
Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis
JC Su, AC Mar, SH Wu, WT Tai, PY Chu, CY Wu, LM Tseng, TC Lee, KF Chen, CY Liu, HC Chiu, CW Shiau
Scientific Reports 2016
Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression
R Rupaimoole, C Ivan, D Yang, KM Gharpure, SY Wu, CV Pecot, RA Previs, AS Nagaraja, GN Armaiz-Pena, M McGuire, S Pradeep, LS Mangala, C Rodriguez-Aguayo, L Huang, M Bar-Eli, W Zhang, G Lopez-Berestein, GA Calin, AK Sood
Oncogene 2016
Future options of anti-angiogenic cancer therapy
Y Cao
Chinese journal of cancer 2016
Physical and Chemical Signals That Promote Vascularization of Capillary-Scale Channels
RM Linville, NF Boland, G Covarrubias, GM Price, J Tien
Cellular and Molecular Bioengineering 2016
Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial
JH Zhong, XK Du, BD Xiang, LQ Li
World journal of hepatology 2016
Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)
E Maj, D Papiernik, J Wietrzyk
International journal of oncology 2016
Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?
GA Bjarnason
Canadian Urological Association Journal 2016
ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics
C Porta, S Chiellino
Annals of translational medicine 2016
Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab†
C Balaña, A Estival, E Pineda, J Sepúlveda, C Mesía, S del Barco, M Gil-Gil, M Hardy, A Indacoechea, AF Cardona
Neuro-Oncology Practice 2016
Dissecting the Contribution of Vascular Alterations and Aging to Alzheimer’s Disease
C Janota, CA Lemere, MA Brito
Molecular Neurobiology 2015
Molecular Mechanisms of Preeclampsia
T Hod, AS Cerdeira, SA Karumanchi
Cold Spring Harbor Perspectives in Medicine 2015
Adaptation to antiangiogenic therapy in neurological tumors
PM Flanigan, MK Aghi
Cellular and Molecular Life Sciences 2015
Combined Effects of Pericytes in the Tumor Microenvironment
AL Ribeiro, OK Okamoto
Stem Cells International 2015
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
Y Zhao, AA Adjei
The oncologist 2015
Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
A Mitsuhashi, H Goto, A Saijo, VT Trung, Y Aono, H Ogino, T Kuramoto, S Tabata, H Uehara, K Izumi, M Yoshida, H Kobayashi, H Takahashi, M Gotoh, S Kakiuchi, M Hanibuchi, S Yano, H Yokomise, S Sakiyama, Y Nishioka
Nature Communications 2015
Tumor refractoriness to anti-VEGF therapy
D Ribatti
Oncotarget 2015
Cancer Treatment and Research
L Miao, L Huang
Cancer treatment and research 2015
Autophagy, a double-edged sword in anti-angiogenesis therapy
J Liu, L Fan, H Wang, G Sun
Medical Oncology 2015
Involvement of Corneal Lymphangiogenesis in a Mouse Model of Allergic Eye Disease
HS Lee, D Hos, T Blanco, F Bock, NJ Reyes, R Mathew, C Cursiefen, R Dana, DR Saban
Investigative ophthalmology & visual science 2015
Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature
EI Deryugina, JP Quigley
Matrix Biology 2015
Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours
O Coutelle, LM Schiffmann, M Liwschitz, M Brunold, V Goede, M Hallek, H Kashkar, UT Hacker
British Journal of Cancer 2015
Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge
V Marotta, A Colao, A Faggiano
Endocrine 2015
Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study
R Petrioli, E Francini, AI Fiaschi, L Laera, L Luzzi, P Paladini, C Ghiribelli, L Voltolini, V Bianco, G Roviello
Medical Oncology 2015
Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
T Otsuka, S Nakashita, K Yanagita, K Ario, H Kawasoe, S Kawazoe, Y Eguchi, T Mizuta
Diseases 2015
Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer
G Roviello, E Francini, A Perrella, L Laera, MA Mazzei, S Guerrini, F Roviello, D Marrelli, R Petrioli
Cancer biology & therapy 2015
Compensatory angiogenesis and tumor refractoriness
RN Gacche
Oncogenesis 2015
Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature
MH Khattab, AE Marciscano, SS Lo, M Lim, JJ Laterra, LR Kleinberg, KJ Redmond
Case Reports in Oncological Medicine 2015
Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy
EL Pollom, L Deng, RK Pai, JM Brown, A Giaccia, BW Loo, DB Shultz, QT Le, AC Koong, DT Chang
International journal of radiation oncology, biology, physics 2015
Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma
HL Gardner, CA London, RA Portela, S Nguyen, MP Rosenberg, MK Klein, C Clifford, DH Thamm, DM Vail, P Bergman, M Crawford-Jakubiak, C Henry, J Locke, LD Garrett
BMC veterinary research 2015
Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis
T Tabouret, T Gregory, M Dhooge, C Brezault, O Mir, J Dréanic, S Chaussade, R Coriat
Investigational New Drugs 2015
Molecular control of capillary morphogenesis and maturation by recognition and remodeling of the extracellular matrix: functional roles of endothelial cells and pericytes in health and disease
GE Davis, PR Norden, SL Bowers
Connective Tissue Research 2015
An exceptional overall survival using bevacizumab beyond progression in a patient with Non-small cell lung cancer
G Roviello, E Francini, A Perrella, L Laera, MA Mazzei, S Guerrini, R Petrioli
Cancer biology & therapy 2015
Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials
Q Gao, L Zhao, W Li, H Zhang, N Hou, L Guo
OncoTargets and therapy 2015
Tenascin-C: Exploitation and collateral damage in cancer management
C Spenlé, F Saupe, K Midwood, H Burckel, G Noel, G Orend
Cell adhesion & migration 2015
Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization
Shao R, Taylor SL, Oh DS, Schwartz LM
Oncotarget 2015
AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients
Benoit Langlois, Falk Saupe, Tristan Rupp, Christiane Arnold, Michaël van der Heyden, Gertraud Orend, Thomas Hussenet
Oncotarget 2014
Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models
E Ciamporcero, KM Miles, R Adelaiye, S Ramakrishnan, L Shen, S Ku, S Pizzimenti, B Sennino, G Barrera, R Pili
Molecular cancer therapeutics 2014
Hypoxic Signaling During Tissue Repair and Regenerative Medicine
T Nauta, V Hinsbergh, P Koolwijk
International journal of molecular sciences 2014
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
NS Vasudev, AR Reynolds
Angiogenesis 2014
Resveratrol and Arsenic Trioxide Act Synergistically to Kill Tumor Cells In Vitro and In Vivo
XY Zhao, S Yang, YR Chen, PC Li, MM Dou, J Zhang, A Ahmad
PloS one 2014
Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors
A Wicki, D Wild, V Prêtre, R Mansi, A Orleth, JC Reubi, C Rochlitz, C Mamot, HR Mäcke, G Christofori
EJNMMI Research 2014
Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation:
J Nakade, S Takeuchi, T Nakagawa, D Ishikawa, T Sano, S Nanjo, T Yamada, H Ebi, L Zhao, K Yasumoto, K Matsumoto, K Yonekura, S Yano
Journal of Thoracic Oncology 2014
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma
S Marinelli, V Salvatore, MB Toaldo, M Milazzo, L Croci, L Venerandi, A Pecorelli, C Palamà, A Diana, L Bolondi, F Piscaglia
BMC Cancer 2014
MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression
Y Peng, JJ Guo, YM Liu, XL Wu
Bioscience Reports 2014
Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials
SR Patel, AB Karnad, NS Ketchum, BH Pollock, J Sarantopoulos, S Weitman, D Mahalingam
Journal of Gastrointestinal Oncology 2014
HRES-1/Rab4 promotes the formation of LC3(+) autophagosomes and the accumulation of mitochondria during autophagy
G Talaber, G Miklossy, Z Oaks, Y Liu, SA Tooze, DM Chudakov, K Banki, A Perl
PloS one 2014
Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2
JC Doloff, CS Chen, DJ Waxman
Molecular Cancer 2014
Bevacizumab: A Review of Its Use in Advanced Cancer
GM Keating
Drugs 2014
Cell-sheet Therapy With Omentopexy Promotes Arteriogenesis and Improves Coronary Circulation Physiology in Failing Heart
S Kainuma, S Miyagawa, S Fukushima, J Pearson, YC Chen, A Saito, A Harada, M Shiozaki, H Iseoka, T Watabe, H Watabe, G Horitsugi, M Ishibashi, H Ikeda, H Tsuchimochi, T Sonobe, Y Fujii, H Naito, K Umetani, T Shimizu, T Okano, E Kobayashi, T Daimon, T Ueno, T Kuratani, K Toda, N Takakura, J Hatazawa, M Shirai, Y Sawa
Molecular Therapy 2014
Effect of Endostar combined with angiopoietin-2 inhibitor on malignant pleural effusion in mice
SC Fang, HT Zhang, HD Hu, CY Wang, YM Zhang
Medical Oncology 2014
Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression
R Rupaimoole, SY Wu, S Pradeep, C Ivan, CV Pecot, KM Gharpure, AS Nagaraja, GN Armaiz-Pena, M McGuire, B Zand, HJ Dalton, J Filant, JB Miller, C Lu, NC Sadaoui, LS Mangala, M Taylor, T Beucken, E Koch, C Rodriguez-Aguayo, L Huang, M Bar-Eli, BG Wouters, M Radovich, M Ivan, GA Calin, W Zhang, G Lopez-Berestein, AK Sood
Nature Communications 2014
Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma
MJ Hicks, K Funato, L Wang, E Aronowitz, JP Dyke, DJ Ballon, DF Havlicek, EZ Frenk, BP De, MJ Chiuchiolo, D Sondhi, NR Hackett, SM Kaminsky, V Tabar, RG Crystal
Cancer Gene Therapy 2014
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
AB Suttle, HA Ball, M Molimard, TE Hutson, C Carpenter, D Rajagopalan, Y Lin, S Swann, R Amado, L Pandite
British Journal of Cancer 2014
Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours
E Raymond, S Faivre
Current Oncology 2014
Endothelial SRF/MRTF ablation causes vascular disease phenotypes in murine retinae
Christine Weinl, Heidemarie Riehle, Dongjeong Park, Christine Stritt, Susanne Beck, Gesine Huber, Hartwig Wolburg, Eric N. Olson, Mathias W Seeliger, Ralf H. Adams, Alfred Nordheim
Journal of Clinical Investigation 2013
Recent molecular discoveries in angiogenesis and anti-angiogenic therapies in cancer
Jonathan Welti, Sonja Loges, Stefanie Dimmeler, Peter Carmeliet
Journal of Clinical Investigation 2013
Mouse models for studying angiogenesis and lymphangiogenesis in cancer
L Eklund, M Bry, K Alitalo
Molecular Oncology 2013
EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF
LK Gordon, M Kiyohara, M Fu, J Braun, P Dhawan, A Chan, L Goodglick, M Wadehra
Oncogene 2013
Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study
L Moscetti, F Nelli, MA Fabbri, I Sperduti, D Alesini, E Cortesi, D Gemma, T Gamucci, R Grande, I Pavese, D Franco, EM Ruggeri
Investigational New Drugs 2013
Tanycytic VEGF-A Boosts Blood-Hypothalamus Barrier Plasticity and Access of Metabolic Signals to the Arcuate Nucleus in Response to Fasting
F Langlet, BE Levin, S Luquet, M Mazzone, A Messina, AA Dunn-Meynell, E Balland, A Lacombe, D Mazur, P Carmeliet, SG Bouret, V Prevot, B Dehouck
Cell Metabolism 2013
Hypoxia, notch signalling, and prostate cancer
L Marignol, K Rivera-Figueroa, T Lynch, D Hollywood
Nature Reviews Urology 2013
Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues
Y Yang, Y Zhang, Z Cao, H Ji, X Yang, H Iwamoto, E Wahlberg, T Lanne, B Sun, Y Cao
Proceedings of the National Academy of Sciences 2013
Reversibility of regorafenib effects in hepatocellular carcinoma cells
R D’Alessandro, MG Refolo, C Lippolis, C Messa, A Cavallini, R Rossi, L Resta, A Carlo, BI Carr
Cancer Chemotherapy and Pharmacology 2013
Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth
X Yang, Y Zhang, Y Yang, S Lim, Z Cao, J Rak, Y Cao
Proceedings of the National Academy of Sciences 2013
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy
NS Vasudev, V Goh, JK Juttla, VL Thompson, JM Larkin, M Gore, PD Nathan, AR Reynolds
British Journal of Cancer 2013
Double-antiangiogenic protein DAAP targeting vascular endothelial growth factor A and angiopoietins attenuates collagen-induced arthritis
YS Hah, YJ Koh, HS Lim, HO Kim, YH Cheon, HS Noh, KY Jang, SY Lee, GM Lee, GY Koh, SI Lee
Arthritis Research & Therapy 2013
Combining two strategies to improve perfusion and drug delivery in solid tumors
T Stylianopoulos, RK Jain
Proceedings of the National Academy of Sciences 2013
Bevacizumab treatment for advanced non-small cell lung cancer: A case report
Y Fan, Z Huang, W Mao
Oncology Letters 2013
Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
G Tonini, M Imperatori, B Vincenzi, AM Frezza, D Santini
Journal of Experimental & Clinical Cancer Research 2013
Status of targeted therapies in the adjuvant treatment of colon cancer
VM Nelson, AB 3rd
Journal of Gastrointestinal Oncology 2013
Vascular islands during microvascular regression and regrowth in adult networks
MR Kelly-Goss, RS Sweat, MS Azimi, WL Murfee
Frontiers in physiology 2013
A review of tasquinimod in the treatment of advanced prostate cancer
SC Williamson, AE Hartley, R Heer
Drug design, development and therapy 2013
A liver HIF-2α/IRS2 pathway sensitizes hepatic insulin signaling and is modulated by VEGF inhibition
K Wei, SM Piecewicz, LM McGinnis, CM Taniguchi, SJ Wiegand, K Anderson, CW Chan, KX Mulligan, D Kuo, J Yuan, M Vallon, L Morton, E Lefai, MC Simon, JJ Maher, G Mithieux, F Rajas, J Annes, OP McGuinness, G Thurston, AJ Giaccia, CJ Kuo
Nature Medicine 2013
[The targets research of non-small cell lung cancer targeted therapy]
Hongsheng Xue, Shaohua Zhou, Wanpeng Lu, Zhilong Zhao
Zhongguo fei ai za zhi = Chinese journal of lung cancer 2013
Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase
Y Awazu, A Mizutani, Y Nagase, S Tsuchiya, K Nakamura, Y Kakoi, O Kitahara, T Takeuchi, S Yamasaki, N Miyamoto, H Iwata, H Miki, S Imamura, A Hori
Cancer Science 2013
Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells.
Kaulfuß S, Seemann H, Kampe R, Meyer J, Dressel R, König B, Scharf JG, Burfeind P
Oncotarget 2013
Role of Bone Marrow-Derived Cells in Angiogenesis: Focus on Macrophages and Pericytes
Y Ding, N Song, Y Luo
Cancer Microenvironment 2012
Primary Xenografts of Human Prostate Tissue as a Model to Study Angiogenesis Induced by Reactive Stroma
VP Montecinos, A Godoy, J Hinklin, RR Vethanayagam, GJ Smith
PloS one 2012
Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target: Figure 1
B Sitohy, JA Nagy, HF Dvorak
Cancer research 2012
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane
Y Suzuki, T Saeki, K Aogi, M Toi, H Fujii, K Inoue, T Watanabe, Y Fujiwara, Y Ito, Y Takatsuka, H Iwata, H Arioka, Y Tokuda
International Journal of Clinical Oncology 2012
Larger therapeutic window for steroid versus VEGF-A inhibitor in inflammatory angiogenesis: surprisingly similar impact on leukocyte infiltration
S Nakao, S Zandi, N Lara-Castillo, M Taher, T Ishibashi, A Hafezi-Moghadam
Investigative ophthalmology & visual science 2012
Patients With Metastatic Breast Cancer Using Bevacizumab as a Treatment: Is There Still a Role for it?
AE Lohmann, S Chia
Current Treatment Options in Oncology 2012
Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
S Chouaib, Y Messai, S Couve, B Escudier, M Hasmim, MZ Noman
Frontiers in immunology 2012
Anaplastic Thyroid Carcinoma
A Taccaliti, F Silvetti, G Palmonella, M Boscaro
Frontiers in Endocrinology 2012
Emerging role of multikinase inhibitors for refractory thyroid cancer
CA Perez, BA Arango, M Velez, LE Raez, ES Santos
Biologics : targets & therapy 2012
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
V Grünwald, AS Merseburger
OncoTargets and therapy 2012
Small GTPase R-Ras Regulates Integrity and Functionality of Tumor Blood Vessels
J Sawada, T Urakami, F Li, A Urakami, W Zhu, M Fukuda, DY Li, E Ruoslahti, M Komatsu
Cancer Cell 2012
Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC)
RA Pazo-Cid, M Lanzuela, G Esquerdo, JL Pérez-Gracia, A Antón, G Amigo, JM Trufero, AL García-Otín, P Martín-Duque
Clinical and Translational Oncology 2012
Targeting Carcinoma-Associated Fibroblasts Within the Tumor Stroma With a Fibroblast Activation Protein-Activated Prodrug
WN Brennen, DM Rosen, H Wang, JT Isaacs, SR Denmeade
JNCI Journal of the National Cancer Institute 2012
Controlling escape from angiogenesis inhibitors
B Sennino, DM McDonald
Nature Reviews Cancer 2012
Preeclampsia, gestational hypertension and subsequent hypothyroidism
T Männistö, SA Karumanchi, A Pouta, M Vääräsmäki, P Mendola, S Miettola, HM Surcel, A Bloigu, A Ruokonen, MR Järvelin, AL Hartikainen, E Suvanto
Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 2012
Contrast Ultrasound Imaging for Identification of Early Responder Tumor Models to Anti-Angiogenic Therapy
SR Sirsi, ML Flexman, F Vlachos, J Huang, SL Hernandez, HK Kim, TB Johung, JW Gander, AR Reichstein, BS Lampl, A Wang, AH Hielscher, JJ Kandel, DJ Yamashiro, MA Borden
Ultrasound in Medicine & Biology 2012
Combination of Local Transcatheter Arterial Chemoembolization and Systemic Anti-Angiogenic Therapy for Unresectable Hepatocellular Carcinoma
E Liapi, JF Geschwind
Liver Cancer 2012
Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone
E Manley, DJ Waxman
The Journal of pharmacology and experimental therapeutics 2012
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
A Fabi, M Russillo, G Ferretti, G Metro, C Nisticò, P Papaldo, FD Vita, G D'Auria, A Vidiri, D Giannarelli, F Cognetti
BMC Cancer 2012
Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG 5910L)
M Takeda, I Okamoto, T Yamanaka, K Nakagawa, Y Nakanishi
BMC Cancer 2012
Targeting angiogenesis in metastatic breast cancer
S Reddy, M Raffin, V Kaklamani
The oncologist 2012
Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α
YJ Kim, HJ Lee, TM Kim, TS Eisinger-Mathason, AY Zhang, B Schmidt, DL Karl, MS Nakazawa, PJ Park, MC Simon, SS Yoon
International Journal of Cancer 2012
Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation
R Francescone, S Scully, B Bentley, W Yan, SL Taylor, D Oh, L Moral, R Shao
The Journal of biological chemistry 2012
Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients
AW Griffioen, LA Mans, AM de Graaf, P Nowak-Sliwinska, CL de Hoog, TA de Jong, FA Vyth-Dreese, JR van Beijnum, A Bex, E Jonasch
Clinical cancer research 2012
Anti-angiogenic therapy for cancer: An update
B Al-Husein, M Abdalla, M Trepte, DL DeRemer, PR Somanath
Pharmacotherapy 2012
Anti-VEGF Therapy Revived by c-Met Inhibition, but Is c-Met the Answer?
KD Lynn, RA Brekken
Cancer Discovery 2012
Antitumor effect of FP3 in a patient-derived tumor tissue xenograft model of gastric carcinoma through an antiangiogenic mechanism
K Jin, H Lan, F Cao, Z Xu, NA HAN, G Li, K He, L Teng
Oncology Letters 2012
Concise Drug Review: Pazopanib and Axitinib
RM Geel, JH Beijnen, JH Schellens
The oncologist 2012
Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer:
R Dienstmann, F Ades, KS Saini, O Metzger-Filho
Drug Safety 2012
Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials.
Schmidt B, Lee HJ, Ryeom S, Yoon SS
Current Angiogenesis 2012
The role played by perivascular cells in kidney interstitial injury
Rojas A, Chang FC, Lin SL, Duffield JS
Clinical nephrology 2012
FGF-dependent regulation of VEGF signaling via transcriptional control of VEGF receptor 2 expression
Masahiro Murakami, Loc Nguyen, Kunihiko Hatanaka, William Schachterle, Pei-Yu Chen, Zhen Zhuang, Brian Black, Michael Simons
Journal of Clinical Investigation 2011
Angiogenesis
DR Senger, GE Davis
Cold Spring Harbor perspectives in biology 2011
Regulation of blood vessel sprouting
JC Chappell, DM Wiley, VL Bautch
Seminars in Cell and Developmental Biology 2011
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
JM Ebos, RS Kerbel
Nature Reviews Clinical Oncology 2011
Molecular mechanisms and clinical applications of angiogenesis
P Carmeliet, RK Jain
Nature 2011
Molecular basis for endothelial lumen formation and tubulogenesis during vasculogenesis and angiogenic sprouting
GE Davis, AN Stratman, A Sacharidou, W Koh
International review of cell and molecular biology 2011
Antiangiogenesis Enhances Intratumoral Drug Retention
J Ma, CS Chen, T Blute, DJ Waxman
Cancer research 2011
Characterization of Prox1 and VEGFR-3 expression and lymphatic phenotype in normal organs of mice lacking p50 subunit of NF-κB
MJ Flister, LD Volk, S Ran
Microcirculation (New York, N.Y. : 1994) 2011
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
KD Bock, M Mazzone, P Carmeliet
Nature Reviews Clinical Oncology 2011
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group
R Buckstein, J Kuruvilla, N Chua, C Lee, DA Macdonald, AJ Al-Tourah, AH Foo, W Walsh, SP Ivy, M Crump, EA Eisenhauer
Leukemia & Lymphoma 2011
Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options
F Perri, GD Lorenzo, GD Scarpati, C Buonerba
World journal of clinical oncology 2011
Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases
AM Jubb, A Cesario, M Ferguson, MT Congedo, KC Gatter, F Lococo, A Mulè, F Pezzella
British Journal of Cancer 2011
Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61
LG Harris, LK Pannell, S Singh, RS Samant, LA Shevde
Oncogene 2011
Changes in blood vessel maturation in the fibrous cap of the tumor rim
H Naito, K Takara, T Wakabayashi, H Kawahara, H Kidoya, N Takakura
Cancer Science 2011
Forty-Year Journey of Angiogenesis Translational Research
Y Cao, J Arbiser, RJ D'Amato, PA D'Amore, DE Ingber, R Kerbel, M Klagsbrun, S Lim, MA Moses, B Zetter, H Dvorak, R Langer
Science Translational Medicine 2011
Review: Cerebral microvascular pathology in aging and neurodegeneration
WR Brown, CR Thore
Neuropathology and Applied Neurobiology 2011
Targeting Angiogenesis in Esophagogastric Adenocarcinoma
AF Okines, AR Reynolds, D Cunningham
The oncologist 2011
Methylselenocysteine - a Promising Antiangiogenic Agent for Overcoming Drug Delivery Barriers in Solid Malignancies for Therapeutic Synergy with Anticancer Drugs
A Bhattacharya
Expert Opinion on Drug Delivery 2011
Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors
BL Falcon, S Barr, PC Gokhale, J Chou, J Fogarty, P Depeille, M Miglarese, DM Epstein, DM McDonald
Cancer research 2011
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
WK You, B Sennino, CW Williamson, B Falcón, H Hashizume, LC Yao, DT Aftab, DM McDonald
Cancer research 2011
Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases
K Jin, G Li, B Cui, J Zhang, H Lan, N Han, B Xie, F Cao, K He, H Wang, Z Xu, L Teng, T Zhu
PloS one 2011
Phase III Comparison of Standard Doxorubicin and Cyclophosphamide Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer: SWOG 0012
GK Ellis, WE Barlow, JR Gralow, GN Hortobagyi, CA Russell, ME Royce, EA Perez, D Lew, RB Livingston
Journal of Clinical Oncology 2011
Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis
JC Kesselheim, AD Norden, PY Wen, S Joffe
The oncologist 2011
Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of “Rebound” Revascularization as Mode of Escape
E di Tomaso, M Snuderl, WS Kamoun, DG Duda, PK Auluck, L Fazlollahi, OC Andronesi, MP Frosch, PY Wen, SR Plotkin, ET Hedley-Whyte, AG Sorensen, TT Batchelor, RK Jain
Cancer research 2011
A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers
M Faibish, R Francescone, B Bentley, W Yan, R Shao
Molecular cancer therapeutics 2011
VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer
XB Trinh, PA van Dam, PB Vermeulen, SJ Laere, GG den Eynden, WA Tjalma, LY Dirix
Clinical and Translational Oncology 2011
Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line: Anti-tumour and anti-angiogenetic effects of zoledronic acid
MD Salvatore, A Orlandi, C Bagalà, M Quirino, A Cassano, A Astone, C Barone
Cell Proliferation 2011
Bevacizumab—has it reached its final resting place?
DJ Kerr, AM Young
Nature Reviews Clinical Oncology 2011
In pursuit of new anti-angiogenic therapies for cancer treatment
Cai J, Han S, Qing R, Liao D, Law B, Boulton ME
Frontiers in bioscience : a journal and virtual library 2011
Vascular endothelial growth factor-C induces lymphangitic carcinomatosis, an extremely aggressive form of lung metastases
S Das, DS Ladell, S Podgrabinska, V Ponomarev, C Nagi, JT Fallon, M Skobe
Cancer research 2010
Selective Killing of Tumor Neo-Vasculature Paradoxically Improves Chemotherapy Delivery to Tumors
FE Escorcia, E Henke, MR McDevitt, CH Villa, P Smith-Jones, RG Blasberg, R Benezra, DA Scheinberg
Cancer research 2010
Biology of the adult hepatic progenitor cell: "ghosts in the machine"
H Darwiche, BE Petersen
Progress in molecular biology and translational science 2010
Tumor Angiogenesis: Insights and Innovations
F Nussenbaum, IM Herman
Journal of Oncology 2010
Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer
AR Reynolds
Dose-response : a publication of International Hormesis Society 2010
Molecular Mechanisms of Resistance to Tumour Anti-Angiogenic Strategies
R Grépin, G Pagès
Journal of Oncology 2010
Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates
S Loges, T Schmidt, P Carmeliet
Genes & cancer 2010
Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
C Lu-Emerson, AD Norden, J Drappatz, EC Quant, R Beroukhim, AS Ciampa, LM Doherty, DC LaFrankie, S Ruland, PY Wen
Journal of Neuro-Oncology 2010
Single Agents with Designed Combination Chemotherapy Potential: Synthesis and Evaluation of Substituted Pyrimido[4,5- b ]indoles as Receptor Tyrosine Kinase and Thymidylate Synthase Inhibitors and as Antitumor Agents
A Gangjee, N Zaware, S Raghavan, M Ihnat, S Shenoy, RL Kisliuk
Journal of Medicinal Chemistry 2010
Steroid-resistant lymphatic remodeling in chronically inflamed mouse airways
LC Yao, P Baluk, J Feng, DM McDonald
The American Journal of Pathology 2010
Rapid remodeling of airway vascular architecture at birth
A Ni, E Lashnits, LC Yao, P Baluk, DM McDonald
Developmental dynamics : an official publication of the American Association of Anatomists 2010
A review of string vessels or collapsed, empty basement membrane tubes
WR Brown
Journal of Alzheimer's disease : JAD 2010
Molecular and clinical aspects of targeting the VEGF pathway in tumors
G Korpanty, LA Sullivan, E Smyth, DN Carney, RA Brekken
Journal of Oncology 2010
Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF
C Ward, D Kuehn, RE Burden, JA Gormley, TJ Jaquin, M Gazdoiu, D Small, R Bicknell, JA Johnston, CJ Scott, SA Olwill
PloS one 2010
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study
HJ Hammers, HM Verheul, B Salumbides, R Sharma, M Rudek, J Jaspers, P Shah, L Ellis, L Shen, S Paesante, K Dykema, K Furge, BT Teh, G Netto, R Pili
Molecular cancer therapeutics 2010
Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment
GO Ahn, D Tseng, CH Liao, MJ Dorie, A Czechowicz, JM Brown
Proceedings of the National Academy of Sciences 2010
Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels
WK You, I Kasman, DD Hu-Lowe, DM McDonald
The American Journal of Pathology 2010
Biomimetic hydrogels with pro-angiogenic properties
JJ Moon, JE Saik, RA Poché, JE Leslie-Barbick, SH Lee, AA Smith, ME Dickinson, JL West
Biomaterials 2010
Vascular gene expression patterns are conserved in primary and metastatic brain tumors
Y Liu, EB Carson-Walter, A Cooper, BN Winans, MD Johnson, KA Walter
Journal of Neuro-Oncology 2010
Localization of vascular adhesion protein-1 (VAP-1) in the human eye
L Almulki, K Noda, S Nakao, T Hisatomi, KL Thomas, A Hafezi-Moghadam
Experimental Eye Research 2010
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib
R Coriat, S Ropert, O Mir, B Billemont, S Chaussade, PP Massault, B Blanchet, O Vignaux, F Goldwasser
Investigational New Drugs 2010
Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
RM Zuniga, R Torcuator, R Jain, J Anderson, T Doyle, L Schultz, T Mikkelsen
Journal of Neuro-Oncology 2010
Targeted therapy for locally advanced renal cell carcinoma
E Jonasch, NM Tannir
Targeted Oncology 2010
Off-tumor target—beneficial site for antiangiogenic cancer therapy?
Y Cao
Nature Reviews Clinical Oncology 2010
SLT-VEGF Reduces Lung Metastases, Decreases Tumor Recurrence, and Improves Survival in an Orthotopic Melanoma Model
R Ackerman, JM Backer, M Backer, S Skariah, CV Hamby
Toxins 2010
Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects
B Lemasson, T Christen, X Tizon, R Farion, N Fondraz, P Provent, C Segebarth, EL Barbier, P Genne, O Duchamp, C Remy
NMR in Biomedicine 2010
Androgen deprivation induces rapid involution and recovery of human prostate vasculature
A Godoy, VP Montecinos, DR Gray, P Sotomayor, JM Yau, RR Vethanayagam, S Singh, JL Mohler, GJ Smith
American journal of physiology. Endocrinology and metabolism 2010
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling
RS Bhatt, X Wang, L Zhang, MP Collins, S Signoretti, DC Alsop, SN Goldberg, MB Atkins, JW Mier
Molecular cancer therapeutics 2010
Optical molecular imaging and its emerging role in colorectal cancer
RA Sheth, U Mahmood
American journal of physiology. Gastrointestinal and liver physiology 2010
Understanding the "lethal" drivers of tumor-stroma co-evolution: Emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor microenvironment
MP Lisanti, UE Martinez-Outschoorn, B Chiavarina, S Pavlides, D Whitaker-Menezes, A Tsirigos, AK Witkiewicz, Z Lin, RM Balliet, A Howell, F Sotgia
Cancer biology & therapy 2010
The autophagic tumor stroma model of cancer or “battery-operated tumor growth”: A simple solution to the autophagy paradox
UE Martinez-Outschoorn, D Whitaker-Menezes, S Pavlides, B Chiavarina, G Bonuccelli, C Trimmer, A Tsirigos, G Migneco, AK Witkiewicz, RM Balliet, I Mercier, C Wang, N Flomenberg, A Howell, Z Lin, J Caro, RG Pestell, F Sotgia, MP Lisanti
Cell cycle (Georgetown, Tex.) 2010
Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature
EM Hedlund, K Hosaka, Z Zhong, R Cao, Y Cao
Proceedings of the National Academy of Sciences 2009
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009
Antiangiogenic therapies for high-grade glioma
AD Norden, J Drappatz, PY Wen
Nature Reviews Neurology 2009
The pericyte: cellular regulator of microvascular blood flow
ME Kutcher, IM Herman
Microvascular Research 2009
Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors
B Sennino, F Kuhnert, SP Tabruyn, MR Mancuso, DD Hu-Lowe, CJ Kuo, DM McDonald
Cancer research 2009
Correlative dynamic contrast MRI and microscopic assessments of tumor vascularity in RIP-tag2 transgenic mice
B Sennino, HJ Raatschen, MF Wendland, Y Fu, WK You, DM Shames, DM McDonald, RC Brasch
Magnetic Resonance in Medicine 2009
Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy: Fig. 1
JM Ebos, CR Lee, RS Kerbel
Clinical cancer research 2009
M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis
Y Kubota, K Takubo, T Shimizu, H Ohno, K Kishi, M Shibuya, H Saya, T Suda
Journal of Experimental Medicine 2009
Endothelial cell lumen and vascular guidance tunnel formation requires MT1-MMP-dependent proteolysis in 3-dimensional collagen matrices
AN Stratman, WB Saunders, A Sacharidou, W Koh, KE Fisher, DC Zawieja, MJ Davis, GE Davis
Blood 2009
Update on therapeutic vascularization strategies
EA Phelps, AJ Garcia
Regenerative Medicine 2009
PERK regulates the proliferation and development of insulin-secreting beta-cell tumors in the endocrine pancreas of mice
S Gupta, B McGrath, DR Cavener
PloS one 2009
Bevacizumab and breast cancer: current therapeutic progress and future perspectives
SX Yang
Expert Review of Anticancer Therapy 2009
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
FM Iwamoto, LE Abrey, K Beal, PH Gutin, MK Rosenblum, VE Reuter, LM DeAngelis, AB Lassman
Neurology 2009
Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?
BP Schneider, GW Sledge
Breast Cancer Research 2009
The biology of ovarian cancer: new opportunities for translation
RC Bast, B Hennessy, GB Mills
Nature reviews. Cancer 2009
Treatment in advanced colorectal cancer: what, when and how?
I Chau, D Cunningham
British Journal of Cancer 2009
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
JM Ebos, CR Lee, W Cruz-Munoz, GA Bjarnason, JG Christensen, RS Kerbel
Cancer Cell 2009
Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer
RM Bukowski
Current Oncology Reports 2009
Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer
RS Kerbel
The Breast 2009
VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma
AS Maharaj, TE Walshe, M Saint-Geniez, S Venkatesha, AE Maldonado, NC Himes, KS Matharu, SA Karumanchi, PA D'Amore
Journal of Experimental Medicine 2008
Modes of resistance to anti-angiogenic therapy
G Bergers, D Hanahan
Nature Reviews Cancer 2008
Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation
R Hlushchuk, O Riesterer, O Baum, J Wood, G Gruber, M Pruschy, V Djonov
The American Journal of Pathology 2008
Tumor Angiogenesis
RS Kerbel
New England Journal of Medicine 2008
Vascular effects of photodynamic and pulsed dye laser therapy protocols
J Channual, B Choi, K Osann, D Pattanachinda, J Lotfi, KM Kelly
Lasers in Surgery and Medicine 2008
High-grade glioma before and after treatment with radiation and Avastin: initial observations
I Fischer, CH Cunliffe, RJ Bollo, S Raza, D Monoky, L Chiriboga, EC Parker, JG Golfinos, PJ Kelly, EA Knopp, ML Gruber, D Zagzag, A Narayana
Neuro-oncology 2008
Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth
M Segarra, CK Williams, ML la Sierra, M Bernardo, PJ McCormick, D Maric, C Regino, P Choyke, G Tosato
Blood 2008
FGF-2 triggers PDGF-BB-induced angiogenesis and their reciprocal interplay synergistically promotes tumor neovascularization and metastasis
Lars Johan Nissen, Renhai Cao, Eva-Maria Hedlund, Zongwei Wang, Xing Zhao, Daniel Wetterskog, Keiko Funa, Ebba Bråkenhielm and Yihai Cao
Journal of Clinical Investigation 2007
Angiogenesis modulates adipogenesis and obesity
Yihai Cao
Journal of Clinical Investigation 2007
Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102
B Sennino, BL Falcón, D McCauley, T Le, T McCauley, JC Kurz, A Haskell, DM Epstein, DM McDonald
Cancer research 2007
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
JM Ebos, CR Lee, JG Christensen, AJ Mutsaers, RS Kerbel
Proceedings of the National Academy of Sciences 2007
Roles for VEGF in the adult
AS Maharaj, PA D'Amore
Microvascular Research 2007
Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease
B Thébaud, SH Abman
American journal of respiratory and critical care medicine 2007
Endothelial stomatal and fenestral diaphragms in normal vessels and angiogenesis
RV Stan
Journal of Cellular and Molecular Medicine 2007
Mechanisms of adverse effects of anti-VEGF therapy for cancer
T Kamba, DM McDonald
British Journal of Cancer 2007
Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eye
FE Wang, G Shi, MR Niesman, DA Rewolinski, SS Miller
Experimental Eye Research 2007
Pulmonary gas transfer related to markers of angiogenesis during the menstrual cycle
S Farha, K Asosingh, D Laskowski, L Licina, H Sekiguchi, H Sekigushi, DW Losordo, RA Dweik, HP Wiedemann, SC Erzurum
Journal of applied physiology 2007
Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization
JS Jaggi, E Henke, SV Seshan, BJ Kappel, D Chattopadhyay, C May, MR McDevitt, D Nolan, V Mittal, R Benezra, DA Scheinberg
PloS one 2007
The Importance of Long-Term Monitoring to Evaluate the Microvascular Response to Light-Based Therapies
B Choi, W Jia, J Channual, KM Kelly, J Lotfi
Journal of Investigative Dermatology 2007
Imaging Tumor Angiogenesis
Kristy Red-Horse and Napoleone Ferrara
Journal of Clinical Investigation 2006
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
Yoshihiro Wada, Kenichiro Tanoue, Wataru Takahashi, Masatoshi Eto
Translational andrology and urology
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer: BEVACIZUMAB IN HER2- METASTATIC BREAST CANCER
T Gamucci, L Mentuccia, C Natoli, I Sperduti, A Cassano, A Michelotti, LD Lauro, D Sergi, A Fabi, MG Sarobba, P Marchetti, M Barba, E Magnolfi, M Maugeri-Saccà, E Rossi, V Sini, A Grassadonia, D Pellegrini, A Astone, C Nisticò, F Angelini, A Vaccaro, A Pellegrino, CD Angelis, M Palleschi, L Moscetti, I Bertolini, S Buglioni, A Giordano, L Pizzuti, P Vici
Journal of Cellular Physiology 2016
The regulation of the mitochondrial apoptotic pathway by glucocorticoid receptor in collaboration with Bcl-2 family proteins in developing T cells
L Prenek, F Boldizsár, R Kugyelka, E Ugor, G Berta, P Németh, T Berki
Apoptosis 2016
Pharmacologic resistance in colorectal cancer: a review
WA Hammond, A Swaika, K Mody
Therapeutic advances in medical oncology 2015
Walking the Line: A Fibronectin Fiber-Guided Assay to Probe Early Steps of (Lymph)angiogenesis
M Mitsi, MM Schulz, E Gousopoulos, AM Ochsenbein, M Detmar, V Vogel, CL Addison
PloS one 2015
Peering into the aftermath: The inhospitable host?
RS Kerbel, JM Ebos
Nature Medicine 2010
Bevacizumab
F KazaziHyseni, JH Beijnen, JH Schellens
The oncologist 2010
Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study.
Blankenberg FG, Levashova Z, Sarkar SK, Pizzonia J, Backer MV, Backer JM
Translational oncology 2010
Molecular Therapies in Thyroid Cancer
Huyck T, Agulnik M
Pharmaceuticals 2010
A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo.
Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C, Stevens B, Julien S, Franke S, Meengs B, Brody J, Presnell S, Hamacher NB, Lantry M, Wolf A, Bukowski T, Rosler R, Yen C, Anderson-Haley M, Brasel K, Pan Q, Franklin H, Thompson P, Dodds M, Underwood S, Peterson S, Sivakumar PV, Snavely M
mAbs 2010
Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery
A Bex, AA van der Veldt, C Blank, AJ van den Eertwegh, E Boven, S Horenblas, J Haanen
World Journal of Urology 2009
Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: Experimental models and clinical perspectives
Ahn GO, Brown JM
Cell cycle (Georgetown, Tex.) 2009
Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
EE Cohen, LS Rosen, EE Vokes, MS Kies, AA Forastiere, FP Worden, MA Kane, E Sherman, S Kim, P Bycott, M Tortorici, DR Shalinsky, KF Liau, RB Cohen
Journal of Clinical Oncology 2008
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab.
Escudier B, Cosaert J, Jethwa S
Biologics : targets & therapy 2008
Nab-paclitaxel Efficacy in the Orthotopic Model of Human Breast Cancer Is Significantly Enhanced By Concurrent Anti-Vascular Endothelial Growth Factor A Therapy
Volk LD, Flister MJ, Bivens CM, Stutzman A, Desai N, Trieu V, Ran S
Neoplasia (New York, N.Y.) 2008
Erratum
Journal of Cellular and Molecular Medicine 2008
Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor‐β receptor inhibitor on extravasation of nanoparticles from neovasculature
Kano MR, Komuta Y, Iwata C, Oka M, Shirai Y, Morishita Y, Ouchi Y, Kataoka K, Miyazono K
Cancer Science 2008

← Previous 1 2 3 … 14 15 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 3 patents
Referenced in 1 Wikipedia pages
Highlighted by 1 platforms
279 readers on Mendeley
See more details